Nuvation Bio: Welcoming Dr. Robert Mashal to Drive Innovation in Oncology Therapeutics

In a move that bolsters their already impressive team of experts, Nuvation Bio Inc. (NYSE: NUVB) is thrilled to announce the appointment of Dr. Robert Mashal to its esteemed Board of Directors. Known for their groundbreaking work in oncology, Nuvation Bio is a biopharmaceutical company dedicated to developing innovative and differentiated therapeutic candidates to address unmet needs in cancer treatment.

The addition of Dr. Mashal brings a wealth of experience and knowledge to Nuvation Bio. As a seasoned biotech industry veteran, he has served in various leadership roles throughout his career, including CEO of NKT Therapeutics and Alinea Pharmaceuticals. Dr. Mashal's extensive background also includes being a partner at Boston Millennia Partners, where he contributed to the success of several life sciences firms.

At Sanofi, Dr. Mashal held the position of Global Head of Strategy for the Immunology and Oncology franchises, further solidifying his expertise in these areas. Additionally, he has served as a Program Executive at Vertex Pharmaceuticals and as a consultant at McKinsey and Company.

Dr. Mashal's impressive qualifications extend beyond his corporate achievements. He is a board-certified medical oncologist and received his medical training from prestigious institutions such as the University of California, San Francisco, and the Dana-Farber Cancer Institute. His educational background includes degrees from Johns Hopkins University, where he obtained both his B.A. and M.D.

The team at Nuvation Bio is excited to work alongside Dr. Mashal, benefiting from his diverse skill set and unique perspective. His experience as an investor, operator, and medical oncologist will undoubtedly provide valuable insights as Nuvation Bio continues to advance its pipeline of innovative oncology therapeutics.

As a trailblazer in the field, Nuvation Bio is at the forefront of developing therapeutic candidates to address the unmet needs in oncology. Their novel drug-drug conjugate platform is particularly noteworthy, demonstrating their commitment to finding new and effective treatment options for patients.

With a proprietary portfolio that includes mechanistically distinct oncology therapeutic product candidates, Nuvation Bio is well-positioned to tackle some of the most challenging-to-treat types of cancer. Led by Founder, President, and Chief Executive Officer, Dr. David Hung, who previously founded Medivation, Inc., the company remains dedicated to making a profound impact on the lives of cancer patients.

Nuvation Bio's work doesn't stop there. They have offices in both New York and San Francisco, strategically positioning themselves in key locations within the biopharmaceutical industry. Their commitment to innovation and the pursuit of groundbreaking therapies sets them apart as a leader in the field.

For more information about Nuvation Bio and their groundbreaking work in oncology, please visit their website at www.nuvationbio.com. With their distinguished Board of Directors now including Dr. Robert Mashal, Nuvation Bio is well-positioned to continue driving advancements in oncology therapeutics and bringing much-needed solutions to patients around the world.